Selinexor's Myelofibrosis Data Shines, Upside Potential episode artwork

EPISODE · May 4, 2026 · 2 MIN

Selinexor's Myelofibrosis Data Shines, Upside Potential

from The Daily News Now! Business

Karyopharms Q1 2025 earnings highlight selinexors potential in myelofibrosis, with promising Phase 2 trial results showing improved spleen volume reduction, symptom relief, and better blood counts. The company aims to enroll SENTRY trial by June/July, with data expected by year-end/early 2026. Peak US sales potential in MF could reach $1 billion. Despite lower-than-expected revenue guidance, Karyopharm remains focused on its Phase 3 trials and potential blockbuster opportunities. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/9d80325db705dc3b

NOW PLAYING

Selinexor's Myelofibrosis Data Shines, Upside Potential

0:00 2:19

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Daily News Now! Business?

This episode is 2 minutes long.

When was this The Daily News Now! Business episode published?

This episode was published on May 4, 2026.

What is this episode about?

Karyopharms Q1 2025 earnings highlight selinexors potential in myelofibrosis, with promising Phase 2 trial results showing improved spleen volume reduction, symptom relief, and better blood counts. The company aims to enroll SENTRY trial by...

Can I download this The Daily News Now! Business episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!